34 results about "Cannabielsoin" patented technology

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD ap-pears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocan-nabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

This document provides methods and compositions for neuroprotection. The neuroprotective composition may be or include cannabinol or a derivative thereof. The neuroprotective composition may be used in the treatment of neurodegenerative diseases. It may be used to protect retinal neurons from degeneration in individuals who require it, such as in the treatment of glaucoma.

The invention provides a pharmaceutical formulation containing a particulate porous adsorbent selected from the group of aluminosilicates and their salts, with a neutral or basic pH and a particle size between 50 and 800 μm, onto which a mixture of polyoxyethylene sorbitan monooleate (polysorbate 80) is applied with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC, and D8-THC. This formulation improves the bioavailability and release profile of the cannabinoids.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

Disclosed herein are compounds having a structure according to Formula IAlso disclosed are methods for making and using the compounds. The compounds may be useful for treating or preventing a disease or condition in a subject, including a neurodegenerative disease or condition, a metabolic disorder, a traumatic brain injury, or cancer.

Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.

The present invention relates to a solid oral pharmaceutical for Tetrahydrocannabinol (API) or any other Cannabinoid (API) with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Tetrahydrocannabinol and other Cannabinoids can be found in a wide range of indications like pain relief, insomnia, anti- depression and others.

Compositions containing cannabinoids and kinase inhibitors are useful for the treatment of hepatocellular carcinoma (HCC). Compositions containing cannabinolic acid (CBNA) and sorafenib act synergistically on HepG2 cells, an in vitro liver cancer model, and on ex vivo patient-derived xenograft (PDX) HCC models. The effects of all of the disclosed compositions are superior to sorafenib alone, which is the first- and second-line chemotherapeutic agent for the treatment of HCC.

The present invention relates to a transformed recombinant microorganism capable of producing cannabidiolic acid, and a method for producing cannabidiolic acid by using same. More specifically, the present invention relates to a recombinant microorganism capable of synthesizing cannabidiolic acid from cannabigerolic acid without hemp by using a recombinant vector containing a codon-optimized gene that encodes a cannabidiolic acid synthase.

This disclosure generally relates to gas-phase methods to simultaneously purify and decarboxylate cannabinoids in about two seconds, which are about 100-10,000 times more efficient than conventional purification and decarboxylation strategies. The methods also recover thermolabile cannabinoids such as cannabigerol at significantly higher yields than conventional methods.

Methods for the production of cannabichromene and related cannabinoid compounds are disclosed. The methods include: forming a reaction mixture comprising 3,7-dimethylocta-2,6-dienal, a diamine, and olivetol or a related starting material; and maintaining the reaction mixture under conditions sufficient to form the desired product. Methods of the present disclosure may also include one-pot conversion of cannabichromene-type products to cannabinol-type products.

Provided are methods of preparing cannabinol from cannabidiol and / or tetrahydrocannabinol and for preparing cannabinol acetate. The methods comprise using catalytic molecular halogen in the presence of an oxidant.

This invention provides enzymes and methods for synthesizing cannabinoids specifically and in high yield. [Solution] A method is provided for producing one or more cannabinoids, comprising the step of contacting cannabigerol acid with a cannabinoid synthase ortholog. The cannabinoid synthase ortholog is derived from an organism other than hemp (Cannabis sativa). Also disclosed are recombinant cells of Saccharomyces cerevisiae or Pichia pastoris, which contain nucleic acids encoding the cannabinoid synthase ortholog in their genome. The cannabinoid synthase ortholog is expressed in its active form in the recombinant cells.

Hexahydrocannabinol (HHC), hexahydrocannabidiol (H4CBD), and hexahydrocannabidivarin (H4CBDV) derivatives are disclosed. Also disclosed are pharmaceutical compositions comprising such derivatives. Further described are methods of use thereof for treatment and prevention of cancer, including pancreatic and lung cancer.

Disclosed is an aptamer capable of binding to Cannabielsoin (CBE), wherein the aptamer is: an RNA aptamer having a nucleotide sequence of: CGCGGGCAGUGNNNUGCANNNNNNNNUGUGNNNUAUUAGC (SEQ ID NO: 1); or a DNA aptamer having a nucleotide sequence of: CGCGGGCAGTGNNNTGCANNNNNNNNTGTGNNNTATTAGC (SEQ ID NO: 2), wherein for SEQ ID NO: 1, N is one nucleotide selected from the group consisting of A, G, U and C, and wherein for SEQ ID NO: 2, N is one nucleotide selected from the group consisting of A, G, C and T. Also disclosed is a riboswitch and a DNA expression cassette comprising the aptamer, a composition thereof, and a microbe containing the riboswitch or DNA expression cassette. Further disclosed is a method of detecting CBE produced in a microbe using the aptamer or riboswitch as disclosed herein.

This disclosure describes a cannabinoid-based nanoplatform for treating shingles, designed to enhance bioavailability and controlled release of active ingredients. The composition includes cannabinoids like cannabidiol (CBD) and cannabigerol (CBG), alongside flavonoids, polyphenols, and alkaloids, in oral and topical formulations. The oral capsule combines cannabinoids with polyphenols and flavonoids to provide systemic anti-inflammatory, antiviral, and neuroprotective effects, particularly for nerve pain and inflammation, including postherpetic neuralgia. The topical cream includes cannabinoids, capsaicin, and aloe vera, offering localized relief from pain, itching, and rash. The method targets both systemic and localized symptoms during the acute phase of shingles, aiming to inhibit varicella-zoster virus replication, disrupt viral assembly, and prevent viral release, while also providing immune modulation and anti-inflammatory benefits. The nanoplatform uses nano-emulsification techniques, producing particles smaller than 200 nm to ensure optimal delivery and therapeutic efficacy, offering comprehensive relief for shingles symptoms.

Disclosed herein are novel cannabinol (CBN) analogs, each exhibiting a difference in the level and / or type of interaction with the CB1 receptor as compared with the CB2 receptor, and, as such, provide for a significant reduction in psychoactive effects relative to CBN per se. Also provided are pharmaceutical formulations comprising at least one CBN analog of the invention, at least one optional pharmaceutically acceptable excipient, and, also optionally, an additional beneficial agent, along with methods for treating a subject affected by a condition, disorder, or disease responsive to administration of the CBN analog. Exemplary methods of use include treatment of pain, treatment of endometriosis, treatment of inflammation, and a method for inducing weight loss.

The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a tetrahydrocannabinolic acid (THCA) ester. In some embodiments, the cannabinoid acid ester compound is a cannabigerolic (CBGA) acid ester. In some embodiments, the cannabinoid acid ester compound is a cannabinolic (CBNA) acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, the composition comprising cannabigerol and rivocernib as active ingredients, and a use thereof. The composition according to the present invention is based on the finding that remarkably excellent cancer inhibitory efficacy is exhibited when rivoceranib and cannabigerol and / or cannabidiol are used in combination, and thus a cancer treatment effect can be enhanced using the composition.

Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.

The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and / or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and / or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and / or prevention of malign skin disorders, in particular skin cancer.

The present invention relates to a transformed recombinant microorganism having the ability to produce cannabigerolic acid, and a method for producing cannabigerolic acid using same. More specifically, the present invention relates to a recombinant microorganism capable of sustainably producing cannabigerolic acid with high efficiency even without cultivation of Cannabis sativa L., by employing a modularization vector for optimal expression of a key enzyme gene involved in cannabigerolic acid production.

To provide enzymes and methods for synthesizing cannabinoids with specificity and a high yield.SOLUTION: Provided herein is a method for generating one or more cannabinoids, comprising a step of contacting cannabigerolic acid to a cannabinoid synthase ortholog. The cannabinoid synthase ortholog derives from organisms other than Cannabis sativa. Also disclosed is a recombinant cell of Saccharomyces cerevisiae or Pichia pastoris comprising a nucleic acid encoding the cannabinoid synthase ortholog in the genome. The cannabinoid synthase ortholog is expressed in the recombinant cell in an active form.SELECTED DRAWING: Figure 1

Disclosed herein are compositions comprising a cannabichromene-type cannabinoid. More particularly, the present disclosure relates to compositions comprising a cannabichromene-type cannabinoid and a tetrahydrocannabinol-type cannabinoid.

The present application refers to a composition comprising a therapeutically effective amount of cannabigerol and / or of a synthetic cannabigerol analogue for use in reducing: a) a frequency of calcium sparks in a cell, b) a number of calcium sparks per spark site in a cell, c) an intensity and / or a frequency of calcium waves in a cell, or d) any combination thereof. The present application also refers to said composition for use in the treatment and / or prevention of a cardiac arrhythmia.

The application discloses a method for effectively separating cannabidiol, cannabidivarin and tetrahydrocannabinol. The application uses a chromatographic separation and purification method, uses a coordination resin as a filler, and uses a mixed solution of polar and non-polar solvents as an eluent, so as to separate a cannabidiol pure product with a purity of greater than or equal to 99% from a cannabidiol crude product. The cannabidiol and the analogs tetrahydrocannabinol and cannabidivarin are completely separated by one-step purification. The ligand in the coordination resin is used to form a coordination complex with CBD, so that the retention time difference between CBD, THC and CBDV is increased, and thus a good separation effect is achieved. The CBD, CBDV and THC can be completely separated by selecting specific coordination resins and specific elution conditions, and the separation selectivity is good. The purity of the cannabidiol obtained by the separation method can be higher than 99%, the yield can be higher than 80%, and the separation method is suitable for the separation and purification of high-purity CBD.

The present invention relates to methods and pharmaceutical compositions for treating conditions in non-human mammals, including seizures, idiopathic epilepsy, anxiety, noise aversion, and separation anxiety. The treatment involves administering cannabinoid compositions comprising at least one cannabinoid selected from cannabidiol (CBD), cannabidivarin (CBDV), cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), and tetrahydrocannabivarin (THCV). Specific embodiments comprise CBD isolate nano-particles with purity greater than 99% of total cannabinoids and particle sizes less than 100 nanometers, suspended in oil-based media, essentially free of tetrahydrocannabinol (THC). Methods include acute treatment for noise aversion administered immediately prior to or during noise events, and daily administration for separation anxiety management. A pharmaceutical composition comprising CBD, CBDV, and CBC in a 5:1:1 weight ratio for treating seizures and idiopathic epilepsy is disclosed. The compositions may be administered orally, sublingually, or topically at dosages of 0.1 to 10 mg per kg body weight in cats, dogs, and horses.

Compositions and methods for treating or reducing symptoms of acute respiratory distress syndrome (ARDS) generally and COVID-19 infection, in particular, are provided. An exemplary method includes administering to the subject an effective amount of cannabichromene to reduce acute respiratory distress caused by ARDS generally and COVID-19 infection, in particular.

The present invention relates to improved method of treating breakthrough cancer pain. In particular the present invention relates to methods and devices for the treatment of breakthrough cancer pain through inhalation of tetrahydrocannabinol.